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Rhabdomyosarcoma (RMS) is themost common type of soft tissue sarcoma in children and can be divided into twomain subtypes:
embryonal (eRMS) and alveolar (aRMS). Among the cellular heterogeneity of tumors, the existence of a small fraction of cells
called cancer stem cells (CSC), thought to be responsible for the onset and propagation of cancer, has been demonstrated in some
neoplasia. Although the existence of CSC has been reported for eRMS, their existence in aRMS, the most malignant subtype, has
not been demonstrated to date. Given the lack of suitable markers to identify this subpopulation in aRMS, we used cancer stem
cell-enriched supracellular structures (spheres and holoclones) to study this subpopulation.This strategy allowed us to demonstrate
the capacity of both aRMS and eRMS cells to form these structures and retain self-renewal capacity. Furthermore, cells contained
in spheres and holoclones showed significant Hedgehog pathway induction, the inhibition of which (pharmacologic or genetic)
impairs the formation of both holoclones and spheres. Our findings point to a crucial role of this pathway in the maintenance of
these structures and suggest that Hedgehog pathway targeting in CSC may have great potential in preventing local relapses and
metastases.
1. Introduction
Rhabdomyosarcoma (RMS) is the most common type of
soft tissue sarcoma in children and is considered one of
the most prevalent pediatric extracranial solid tumors. RMS
can be divided into two main histopathologic subtypes:
embryonal and alveolar (eRMS and aRMS, resp.). These
subtypes differ considerably in their clinical phenotype and
molecular features. From a molecular point of view, the
majority of aRMS (80% to 85%) contain one of the recip-
rocal chromosomal translocations: either t(2;13)(q35;q14) or
t(1;13)(p36;q14).These translocations generate the anomalous
fusion genes PAX3-FOXO1 and PAX7-FOXO1, respectively
[1, 2]. However, no characteristic translocations have been
described in eRMS. The embryonal subtype is characterized
by the loss of heterozygosity in the short arm of chromosome
11 (11p15.5) [3] and gains in chromosomes 2, 7, 8, 11, 12, 13, and
17 [4].
All the cells contained in a tumor are not identical and
exhibit diverse proliferative and differentiation potential, a
feature commonly referred to as tumor heterogeneity. The
existence of a small fraction of cells—called cancer stem
cells (CSC)—with hierarchical organization and responsible
for the onset and propagation of cancer was first demon-
strated in acute myeloid leukemia [5]. Later, the existence
of cancer stem cells was also described in solid tumors
such as prostate cancer [6], melanoma [7], brain tumors
[8] and breast cancer [9]. According to the clonal evolution
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model, some tumor cells acquire sequential mutations which
progressively confer on them a growth advantage, thereby
promoting tumor progression [10, 11]. On the other hand, the
cancer stem cell hypothesis suggests the existence of a rare
subpopulation of cells with properties of normal stem cells—
self-renewal, high differentiation potential, proliferation, and
chemoresistance—able to initiate a tumor and produce cellu-
lar heterogeneity.Therefore, this model points to cancer stem
cells as the only cell type with actual tumorigenic potential.
Moreover, this subpopulation could also be, always according
to this theory, responsible for the formation of local relapses
and metastases [10–12]. However, these two models are not
mutually exclusive, since tumor stem cells may also undergo
clonal evolution.
Childhood cancers have specific characteristics that
define them as entities differing strongly from adult malig-
nancies owing to their different etiology, biology, response
to treatment, and outcome. Given these differences, we
must question whether cancer stem cells exist in pediatric
cancers and, if so, whether their function is similar in
pediatric and adult malignancies. For the particular case of
RMS, controversy exists as to suitable markers for stem cell
isolation. Thus, Hirotsu et al. [13] were the first to describe
the existence of tumor-initiating cells in eRMS and proposed
FGFR3 as a suitable marker for their isolation. Later, Walter
et al. rebutted the possibility of using FGFR3 as a stem cell
marker inRMS, andproposedCD133/2 as an isolationmarker
for this subpopulation [12]. Pressey et al. [14] confirmed the
presence of CD133-positive myogenic precursors in RMS cell
lines. However, a recent work demonstrated that CD133-
positive cells were not able to generate tumorsmore efficiently
(than CD133 negative cells) in immunodeficient mice. Those
authors proposed the transcription factor SOX2 as a cancer
stem cell marker in RMS, Ewing’s sarcoma and osteosarcoma
[15]. Interestingly, the existence of CSC in alveolar RMS has
not been demonstrated to date despite the efforts of the
scientific community working in this field, indicating the
possibility of a lack of suitable markers to identify this rare
subpopulation.
The method of stem cell enrichment based on the ability
of neural stem cells to grow in suspension, forming charac-
teristic spheroids, was first described by Reynolds and Weiss
[16]. It is considered that only stem cells have the ability to
form spheres when seeded at low density [17]. In recent years,
this property has been confirmed in different malignancies
of the nervous system and breast cancer, among others [18,
19]. Recently, the existence of spheres enriched in tumor-
initiating cells and overexpressing the epitope CD133/2 has
been reported in eRMS [12]. An alternative test is the colony-
formation capacity of these cells, which depends on the
proliferation and differentiation potential of selected cells
[11]. The classic test involves seeding cells at low density,
a condition under which stem cells have greater ability to
form colonies. Furthermore, a relationship between the shape
of the colonies and their stem cell potential has also been
described, thus revealing the existence of three types of clones
with very different proliferative capacity [20]. According
to the compaction, contour, and proliferation capacity of
the colonies, those authors then classified the three types
into holoclones, meroclones, and paraclones. The holoclones
(small and compact, forming a well-defined boundary) had
great ability to replicate. Conversely, paraclones were formed
by scattered cells in clones with indefinite borders which
showed very low proliferative capacity. The third type of
colony containing a mixture of cells with different pro-
liferative capabilities was a transition between holoclones
and paraclones. Some years later, another study revealed
that holoclones generated from keratinocytes were enriched
in stem cells and conserved their capability to self-renew.
Moreover, only stem cells from the follicle were able to
form holoclones [21]. In terms of cancer, several studies
have shown that holoclones formed by glioma cells, prostate
cancer and pancreatic cancer are the only ones able to be
tumorigenic [22–24]. The ability of cells to form holoclones
in pediatric sarcomas has not been reported to date.
Some signaling pathways, characterized by their capacity
to orchestrate normal stem cell self-renewal and proliferation,
are also crucial to initiate tumors when they are deregulated.
Among them, the Hedgehog (HH) pathway has been shown
to be preponderant in stem cell self-renewal programs [11].
Recently, involvement of this pathway in stem cell mainte-
nance in various cancers has also been demonstrated [25].
HH signaling was first described in Drosophila [26] and
HH genes are considered to be key regulators of several
development processes. HH signaling also plays important
roles in adult organisms such as stem cell maintenance,
tissue repair and regeneration. In the absence of active SMO
in the membrane, GLI family (GLI1, GLI2, and GLI3) are
proteosomically processed. Upon binding of an HH ligand,
active SMO is detected in the membrane and prevents GLI
proteosomal processing. GLI is then translocated to the
nucleus where it binds to GLI-specific promoters [27–29].
The initial link between HH signaling and human cancers
was established when mutations in human PTCH1 were
found to be associated with a rare hereditary disease called
Gorlin’s syndrome. Patients with Gorlin’s syndrome have a
high incidence of basal cell carcinoma, medulloblastoma and
RMS [30–32]. However, mutation of components of the HH
pathway in RMS is rare, except in Gorlin’s syndrome that
accounts for a very low percentage of RMS patients. HH
pathway alterations, typified by loss of function of PTCH
and SUFU or activating mutations in SMO, HH, or GLI,
are thought to be oncogenic in a considerable number of
other cancers [33]. Currently, consistent activation of the
pathway is well established and generally accepted in RMS
[34]. Moreover, several publications combining in vitro and
in vivo works with xenografted RMS models agreed on
the possibility of effectively reducing tumor growth by HH
pathway inhibition [35–37]. During myogenesis, the HH
pathway is involved in regulating the preservation, expansion,
and differentiation of skeletal muscle progenitor cells. The
fact that RMSpresents an aberrant regulation of this signaling
pathway suggests it may play a role in the origin of this
sarcoma and in the maintenance and renovation of this rare
cell subpopulation [38]. Satheesha et al. [39] showed thatHH
signaling modulates eRMS tumor-initiating cell self-renewal.
However, no previous works studied activation of the path-
way in aRMS spheres or holoclones in either RMS subtype.
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The main aim of this work was to demonstrate the
presence of specific subpopulations of cells with CSC char-
acteristics in RMS by describing the capability of RMS
cells to generate holoclones and spheres as well as the
prominentHH pathway activation in cells contained in these
supracellular structures. Both aRMS and eRMS were found
to have different cell populations able to form holoclones,
paraclones, andmeroclones as well as spheres.The role of the
HH pathway was characterized in these particular subpopu-
lations, which pointed to a crucial role of this pathway in their
maintenance.
2. Materials and Methods
2.1. Cell Culture. RH30 (aRMS, PAX3/FOXO1 translocation),
RD (eRMS), and HTB82 (eRMS) cell lines were obtained
from American Type Culture Collection (ATCC) and
CW9019 (aRMS, PAX7/FOXO1 translocation) was generated
inDr. JaclynBiegel’s laboratory. All RMS cell lineswere grown
in MEM media (Biowest), supplemented with 10% fetal
bovine serum (Sigma-Aldrich), 2mM L-glutamine, 1mM
sodium pyruvate, 1x nonessential amino acids, 100U/mL
penicillin, and 0.1mg/mL streptomycin (all reagents from
Biowest). Cells were maintained at 37∘C in a 5% CO2 water-
jacketed incubator.
2.2. Drug Treatments. The SMO inhibitor Sonidegib
(LDE225) was purchased from Selleckchem. The SHH and
IHH blocking antibody MEDI-5304 was kindly provided
by MedImmune. Working concentrations were 15𝜇M for
Sonidegib and 30 𝜇g/mL for MEDI-5304. The control plates
were treated with equal volumes of vehicle. Cells were
pretreated for 48 h before all functional assays. Cells were
not treated during sphere- and holoclone-formation assays.
2.3. Analysis of Cell Viability. Cells were incubated with 2 𝜇g/
mL propidium iodide and analyzed by flow cytometry in a
FACSAria cytometer (BD Bioscience). Results were analyzed
with FCS Express 4 Flow Cytometry software (De Novo
Software).
2.4. Plasmids, Lentiviral Production, and Transduction.
Genetic inhibition of theHH ligands andGLI1was performed
by shRNAs cloned into the lentiviral vector pGIPZ (GE
Dharmacon).The empty vector was used as a control. Briefly,
the cell line used to produce the lentiviral particles (HEK
293T) was transfected with the envelope plasmid pMD2G
(4 𝜇g), the packaging plasmid psPAX2 (8𝜇g), and pGIPZ
transfer vector (12 𝜇g), according to the Lipofectamine 2000
Transfection Reagent manufacturer’s instructions (Thermo
Fisher Scientific). Cell media containing viral particles were
removed after 24 h. After 48 h of infection, positively trans-
duced cells were selected with puromycin (1 𝜇g/mL, Sigma-
Aldrich). Knockdown efficiency of each shRNAwas analyzed
by western blot. The GE Dharmacon IDs of selected clones
were V3LHS 82400 (shSHH), V3LHS 336297 (shIHH),
V3LHS 401021 (shDHH), and V2LHS 262249 (shGLI1).
Functional assays were performed 7 days after infection.
2.5. Clonal Selection. Viable cells were sorted and seeded
at clonal density with FACSAria flow cytometry (BD Bio-
science) in 96-well plates. All apoptotic or nonviable cells
were discarded. After 10 days of incubation, clones were clas-
sified into holoclones,meroclones, or paraclones according to
phenotypic criteria. For secondary colony formation, clones
were trypsinized and seeded again at clonal density in 96-well
plates. Total number and typology of the clones obtainedwere
assessed in triplicate for each cell line. For RNA extraction,
clones were trypsinized and expanded in 6-well plates.
2.6. Sphere-Formation Assay. 104 CW9019 and 103 HTB82
cells were grown in neurobasal media (Thermo Fisher Scien-
tific) supplemented with 2x B27 (Gibco), 2mM L-glutamine,
100U/mL penicillin, 0.1mg/mL streptomycin (Biowest),
20 ng/mL Epidermal Growth Factor (EGF, R&D System), and
10 ng/mL Fibroblast Growth Factor (FGF, Sigma) in 6-well
plates and maintained at 37∘C in a 5% CO
2
water-jacketed
incubator for 1 week.
For secondary sphere formation, spheres were col-
lected, mechanically disaggregated, and seeded at the above-
mentioned density.The number of secondary spheres formed
was counted after 1 week of incubation.The sphere-formation
efficiency of each cell line was tested in triplicate.
2.7. RNA Extraction, Retrotranscription, and Real-Time PCR.
Total RNA from cell lines was extracted using the RNeasy
Mini Kit (Qiagen), following themanufacturer’s instructions.
2 𝜇g of total RNAwas incubated with random primers (Invit-
rogen) for 5min at 70∘Cand reverse-transcripted using 200U
of Moloney murine leukemia virus reverse transcriptase
(Promega) for 1 h at 37∘C. A 40-cycle PCR based on the
TaqMan assay (Applied Biosystems) was performed to detect
SHH, IHH, DHH, andGLI1 (Hs00179843 m1, Hs00745531 s1,
Hs00368306 m1, and Hs00171790 m1 TaqMan assays, resp.).
The housekeeping gene TBP (assay Hs00172424 m1) was
used as internal control. Relative levels of each mRNA
analyzed were quantified by the 2−ΔΔCt method of Livak and
Schmittgen [40]. All samples were tested in triplicate.
2.8. Statistical Analyses. Statistical analyses were performed
using GraphPad Prism software. All data were presented
as mean ± SEM. Statistical significance was determined by
Student’s 𝑡-test. 𝑝 values were considered significant at ∗𝑝 <
0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
3. Results
3.1. RMS Cells Are Able to Form Holoclones and Spheres.
RMS cell lines CW9019, HTB82, RD, and RH30 were seeded
at clonal density to assess their heterogeneity in colony
formation. After approximately 10 days of incubation, all
cell lines showed three distinct colony types based on
morphologic criteria. Compact colonies with clear contours
corresponded to holoclones, whereas colonies formed with
separated cells corresponded to paraclones; intermediate
colonies were meroclones (Figure 1(a)). While meroclones
and paraclones were quite frequent (25–60%), holoclones






















































Figure 1: Formation of holoclones and spheres in RMS cell lines. (a) Representative images of holoclones, meroclones, and paraclones in
CW9019 and HTB82 cell lines. (b) Percentages of clones classified as holoclones, meroclones, or paraclones in CW9019, HTB82, RD, and
RH30 cell lines. (c) Representative images of CW9019 andHTB82 spheres. (d)Number of spheres formed per 1000 cells seeded in neurosphere
media. Data were expressed as mean ± SEM of three independent experiments.
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were the less frequent colony type (1–16%) (Figure 1(b)).
Interestingly, paraclones were not able to grow indefinitely,
and never formed colonies with more than 40–50 cells,
approximately. Given their capacity to clearly form the three
types of clones, CW9019 and HTB82 were selected for
subsequent studies. Both cell lines were also able to form
spheres (Figure 1(c)). The cell line HTB82 showed sphere-
formation efficiency 5-fold greater than CW9019 cells (25
spheres/1000 cells versus 5 spheres/1000 cells) (Figure 1(d)).
3.2. RMS Holoclones and Spheres Were Able to Self-Renew.
Self-renewal is one of the hallmarks of stem cells. Confirming
that cells contained in holoclones and spheres have self-
renewal potential is the clue to assessing their stem cell
potential. The three types of clones were detached, disaggre-
gated, and reseeded at clonal density and secondary clones
were classified and counted. In the two cell lines analyzed,
paraclone-derived cells exclusively produced paraclones (Fig-
ures 2(g) and 2(h)), meroclone-derived cells formed both
meroclones (30.3% and 56.7%, resp.) and paraclones (69.7%
and 43.3%, resp.) (Figures 2(e) and 2(f)), whereas holoclone-
derived cells were able to generate the three types of colonies:
59–53.6% holoclones, 24.8–34.5% meroclones, and 16.2–
11.9% paraclones, in the cell lines CW9019 and HTB82,
respectively (Figures 2(c) and 2(d)). Interestingly, the typol-
ogy of colonies formed from a holoclone presented marked
enrichment in holoclones (from 16% to 59% in CW9019 and
from 9% to 53.6% inHTB82) compared to the initial percent-
ages (Figures 2(a) and 2(b)). Similarly, after disaggregation
and reseeding of spheres, a significant increase in sphere
number was observed in the two cell lines analyzed (Figures
2(i) and 2(j)).
3.3. The Main Effector of HH Pathway (GLI1) Is Upregulated
in RMS Holoclones and Spheres. The mRNA levels of HH
ligands—SHH, IHH, and DHH—and the HH target gene
GLI1 were analyzed in CW9019 and HTB82 holoclones and
spheres and compared to the levels in meroclones or adher-
ent cells, respectively. Although holoclones presented high
expression levels of HH ligands (results not shown), their
levels were similar to those of meroclones, with the excep-
tion of DHH, which showed clear upregulation in HTB82
holoclones (Figures 3(a), 3(b), and 3(c)). Spheres showed
significant upregulation of the three HH ligands in both cell
lines (Figures 3(e), 3(f), and 3(g)). However, GLI1 was clearly
upregulated in both holoclones and spheres (Figures 3(d) and
3(h)), suggesting that HH pathway activation may play an
important role in stemness maintenance in RMS cells.
3.4. HH Pathway Inhibition Impaired the Formation of RMS
Holoclones and Spheres. The genetic downregulation of IHH,
DHH, and GLI1 by shRNA blocked the formation of holo-
clones in both cell lines, whereas SHH silencing produced
no effects (Figures 4(a) and 4(b)). The total number of
colonies was not affected in any condition (Supplementary
Figure S1, A and B, in Supplementary Material available
online at https://doi.org/10.1155/2017/7507380). Conversely,
CW9010 and HTB82 shRNA-expressing cells maintained the
same ability to form spheres as control cells (transfected with
empty vector) (Supplementary Figure 1, C and D). However,
cells transduced with IHH, DHH and GLI1 shRNA vectors
showed a marked reduction in sphere diameter (Figures 4(c)
and 4(d)). All shRNAs showed efficient reduction in their
respective targets (Figures 4(e)–4(h)). Pharmacologic HH
inhibition rendered similar results. Thus, RMS cell lines pre-
treated with Sonidegib (SMO inhibitor) orMEDI-5304 (SHH
and IHH blocking antibody) showed a significant reduction
in holoclone number and a concomitant increase in the
number of the most differentiated clones—meroclones and
paraclones—only significant in the HTB82 cell line (Figures
5(a) and 5(b)), without affecting the total number of clones
(Supplementary Figure 2, A and B); after the initial 2-day
pretreatment, the clone formation assays were performed in
the absence of drug to prevent possible interferences with cell
proliferation during the growth of clones. Likewise, marked
reductions in the number of spheres (Figures 5(c) and 5(d)) as
well as in their diameter (Figures 5(e) and 5(f)) were observed
afterHH pathway inhibition in both cell lines. No significant
decrease in cell viability was observed after either Sonidegib
or MEDI-5304 pretreatment (Supplementary Figure 2, C and
D).
3.5. Expression of Stem Cell Markers in Holoclones. The
expression levels of several stem cell markers were evaluated
in CW9019 and HTB82 cell lines by PCR. Holoclones of
both cell lines showed higher levels of OCT4 and NANOG
compared to total cell lines. PAX7 was also increased in
CW9019 (no expression of this marker was detected in
HTB82). Conversely, KITLG was found to be upregulated
in HTB82 holoclones, but no differences were observed in
CW9019 for this marker (Figure 6). Other stem cell markers
assayed (such as SOX2 and CD133) showed no variations
(data not shown).
4. Discussion
Although the existence of cancer stem cells has been demon-
strated and a growing body of evidence renders it obvious
in some neoplasia, the case of RMS remains a challenge.
Particularly in RMS, the existence of this rare subpopulation
has only been reported for embryonal rhabdomyosarcoma
and no evidence has been provided of its existence in the alve-
olar subtype, the most aggressive and prone-to-metastasizing
formofRMS.Thus, threemarkers ofCSChave been proposed
in eRMS to date: FGFR3, CD133, and SOX2 [12, 13, 15]. FGFR3,
the first CSC marker to be described in RMS, has been ruled
out by subsequent studies [12]. Conversely, CD133+ cells have
been successfully used to define a subpopulation with CSC
properties in eRMS. However, a major drawback in the RMS
field is the lack of useful CSCmarkers for the alveolar subtype,
which has hampered the demonstration of the existence
of this subpopulation in the most aggressive RMS subtype.
Therefore, the use of other approaches, such as the formation
of holoclones and spheres,may be an interesting alternative to
study this subpopulation of cells in aRMS. Furthermore, the
induction (compared to total cell lines) of stem cell markers
6 Stem Cells International
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Figure 2: Self-renewal capacity of cells contained in RMS holoclones and spheres. ((a) and (b)) Initial percentage of the three types of
clones generated in CW9019 and HTB82 cell lines, respectively. Representative images and quantification of secondary clones formed from
holoclones (c and d), meroclones (e and f), and paraclones (g and h) in CW9019 and HTB82 cell lines, respectively. Enrichment in the
secondary sphere fraction obtained in CW9019 (i) and HTB82 (j) cell lines. All experiments were tested in triplicate. Significance: ∗𝑝 < 0.05;
∗∗𝑝 < 0.01.
(especially OCT4 and NANOG) suggests an enrichment of
stem-like cells in the holoclones. The fact that an increase in
stem cell markers was not observed in subsequent passages of
clones suggests a maintenancemechanism of the proportions
of putative stem cells in the clones.
The capability of a specific cell subpopulation to form
holoclones has been reported in some cancers, including
prostate [22], pancreatic [24], breast [41], non-small cell lung
[42], and colorectal cancers [43]. The capability of cells to
form spheres in culture has also been widely reported in
cancer, even for the case of eRMS [12]. Both assays—based
on the formation of supracellular structures—permit the
enrichment of cells belonging to the stem cell subpopulation
and therefore constitute a method for studying their pecu-
liarities. The results presented herein demonstrate for the
first time the capacity of RMS cells to form holoclones, and
also confirm their capability to form spheres. Remarkably,
only a minor percentage of cells (9–16%) was able to form
holoclones, and only 0.5 to 2.5% of cells were able to form
spheres. These low percentages support the hypothesis of
the existence of a particular subpopulation of cells which
would fit with the cancer stem cell theory. Interestingly,
paraclones showed very low capacity to grow, and never
formed colonies withmore than 40–50 cells.This observation
strongly suggests a reduced stemness of the cells contained in
this type of clone. However, a discrepancy was found between
the percentages of both supracellular structures. The lower
efficiency of the sphere formation compared to holoclone
formation may be explained in terms of higher stringency
of the neurobasal media used for sphere cultures [44]. The
fact that the holoclone-formation assay was performed in the
habitual media of cells may explain the higher rates obtained,
given that cells tend to accommodate faster and better in their
habitual media. Moreover, the exclusive capability of cells
from holoclones to form new holoclones is also suggestive of
self-renewal of this fraction of cells. In this respect, the abso-
lute lack of holoclones in cultures generated frommeroclones
or paraclones is particularly noteworthy. Therefore, the only
cells able to originate the three types of colonies were those
contained in holoclones. Furthermore, holoclone fraction
was enriched in cultures derived from purified holoclones. In
a similar fashion, the number of spheres obtained was clearly
increased in subsequent passages from first-round cultured
spheres.
The HH pathway has been previously shown to be
crucial for CSC maintenance in several cancers [45–50].
The results herein presented showed a very clear activation
of the HH pathway in the RMS stem cell-enriched sub-
population (holoclones and spheres). Thus, the main HH
downstream target, the transcription factor GLI1, showed
striking induction of its mRNA levels both in holoclones and
spheres, thereby supporting a leading role of this pathway in
stemness maintenance.GLI1 is known to play a prooncogenic
role in several cancers but is also characterized by its role



















































































































































































































Figure 3: RMS stem-like cells showed GLI1 upregulation. Analysis of SHH, IHH, DHH, and GLI1mRNA levels in holoclones (a, b, c, and d)
and spheres (e, f, g, and h) of CW9010 and HTB82 cell lines. Values were referred to expression levels of meroclones and adherent cells (black
bars), respectively. Data were tested in triplicate and expressed as mean ± SEM. Significance: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
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Figure 4: Effects of HH ligands and GLI1 depletion on RMS holoclone and sphere formation. ((a) and (b)) Plots representing the percentage
of each colony type formed by SHH, IHH, DHH, and GLI1 shRNA-expressing CW9010 and HTB82 cells, respectively. ((c) and (d)) Plots
representing the relative diameter of spheres formed by shRNA-expressing cells. Values were referred to control cells (transfected with pGIPZ
empty vector) and expressed as mean ± SEM of three independent experiments. From (e) to (h) real-time PCRs to assess the downregulation
of all shRNA targets: SHH, IHH, DHH, and GLI1, respectively. Significance: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.































































































































Figure 5: HH pathway inhibitors hindered holoclone and sphere formation. CW9019 and HTB82 cells were pretreated with Sonidegib
(SMO inhibitor) and MEDI-5304 (HH ligand blocking antibody) 48 h prior to holoclone- and sphere-formation assays. ((a) and (b)) Plots
representing the percentage of each colony type formed afterHH pathway inhibitor treatment. Percentages of number (c and d) and diameter
(e and f) of spheres formed after HH pathway inhibitor treatment. Values were referred to control cells (treated with vehicle) and expressed
as mean ± SEM of three independent experiments. Significance: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; referred to holoclones of control cells and #𝑝 < 0.05;
##𝑝 < 0.01 referred to paraclones of control cells.
























Figure 6: Holoclones showed induction of stem cell markers. mRNA levels of OCT4, NANOG, PAX7, and KITLGwere evaluated in CW9019
and HTB82 cell lines. The expression levels of these markers were evaluated by conventional RT-PCR in total cell lines (line) and holoclones
of first (holo1) and second (holo2) passages.
in cancer stem cell maintenance [45, 49]. Furthermore,
GLI1 is able to activate the expression of two transcription
factors, NANOG [51] and SOX2 [49], known to be crucial
for stemness maintenance. Beyond its possible role in cell
stemness maintenance, HH signaling has been shown to be
mutated or deregulated in many cancers in which it may
support cell proliferation, tumor progression, metastasis and
therapeutic resistance [52]. The relationship between HH
signaling and RMS was first described by Hahn et al. in
1996 [30] andwas further characterized inmice heterozygous
for PTCH1 which not only develop features consistent with
Gorlin’s syndrome, but also have a high incidence of eRMS
[32]. A consistent activation of the pathway is well established
and generally accepted in RMS [53]. Recently, Satheesha et
al. reported impaired tumor formation under HH inhibitor
treatment in eRMS [39]. However, the present report is
the first to describe a possible pharmacologic application
of HH inhibitors in reducing the number of stem-like
cells in a PAX7/FOXO1-translocated aRMS cell line, thereby
suggesting that these results could be extrapolated to the
whole aRMS phenotype. Our results strongly suggest that
a therapy based on HH pathway inhibition not only will
act on cell proliferation but also may be able to reduce the
capability of cells to generate new tumors (i.e., local relapses
ormetastasis). Involvement of theHH pathway in the promo-
tion of cell invasiveness, metastasis, and tumor progression—
albeit not in RMS—has previously been demonstrated in
several neoplasia [54–58]. If we take into account the fact
that the main cause of death from sarcoma—as in the
majority of cancers—is the development and progression
of metastasis, a possible therapy which targets both cell
proliferation and tumor-initiating capacity may be a useful
tool for impeding cancer progression, thereby improving
patient survival. Therefore, the results herein presented
reinforce the application of HH pathway inhibitors in RMS
treatment.
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On the other hand, a strong induction of HH ligand
expression in spheres was clearly manifested. In this respect,
evidence has accumulated that aberrant HH secretion by
tumor cells may stimulate stromal cells near the tumor in
a paracrine manner, including stimulation of tumor angio-
genesis, extracellular matrix modification and secretion of
VEGF, among others [59, 60]. We may speculate that, as
spheres grow, cells located in the central part become isolated,
and nutritive deprivation and/or hypoxia may activate this
previously known mechanism of triggering angiogenesis.
Given that holoclones grow in a monolayer, they may not
suffer this nutritional deprivation and therefore may not
activate this mechanism. However, this is mere speculation
and further experiments will be required to support this
hypothesis.
Regarding the possible clinical application of the results
herein presented, the fact that HH pathway pharmacologic
inhibition reduces the formation of both holoclones and
spheres is particularly noteworthy.Thus, both pharmacologic
approaches (SMO inhibitor Sonidegib and HH-blocking
antibody MEDI-5304) showed significant reductions in the
formation of spheres and holoclones. However, although the
genetic inhibition of IHH, DHH and GLI1 hampered the
formation of holoclones, it was able only to reduce sphere
diameter (no decrease in sphere number was observed). This
fact suggests that these Hedgehog components may be more
crucial and specific for the initiation of holoclones than
spheres. In any event, these results support the HH pathway
as a key therapeutic target against RMS stem-like cells. Thus,
our results suggest, for the first time, the possible use of
HH ligand-specific inhibitors to block RMS stemness. In this
respect, antagonists of SMO were entered in phase I and II
clinical trials, with encouraging results inHH-driven neopla-
sia, particularly in medulloblastoma and basal cell carcinoma
(BCC) [61, 62].More recently, the SMO inhibitor Vismodegib
became the first HH signaling pathway-targeting agent to be
approved by the US Food and Drug Administration (FDA)
for the treatment of metastatic or locally advanced BCC [63].
Given that the HH pathway is strongly activated in cancer
stem cells and inhibition of the pathway clearly reduces
CSC, we can affirm that, besides the inhibition of tumor
growth (which is the commonest criterion for selecting the
applicability of a given drug), the use of HH inhibitors may
help to lower the number of cancer stem cells, at least in
RMS. Targeting of this particularly malignant—albeit rare—
subpopulation may have great potential in preventing local
relapses and metastases, thus improving survival.
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